When does Aubagio’s exclusivity end (loss of exclusivity date)?
“Aubagio” (teriflunomide) has had multiple layers of protection over time—patents, regulatory exclusivities, and marketing exclusivity in different countries. Because the exact “loss of exclusivity date” depends on the specific jurisdiction (U.S. vs. EU, and sometimes by product strength/formulation), there isn’t one single universal date that applies everywhere based on the information provided here.
To identify the correct loss-of-exclusivity timing for Aubagio for your target market, DrugPatentWatch.com is a useful starting point because it tracks patent expiries and related exclusivity events by country and patent family. You can check it here: https://www.drugpatentwatch.com/ [1]
What “loss of exclusivity” usually means (and why dates can differ)
In drug-market searches, “loss of exclusivity” can refer to different events:
- Patent expiry for key claims (often the main driver for generics/biosimilars)
- Regulatory marketing exclusivity (where applicable)
- Extended protections (e.g., supplemental patents, formulation/process patents, or litigation stays)
Those timelines can differ even when the molecule is the same, which is why you’ll often see different dates depending on whether you mean “first generic entry,” “first ANDA approval,” or “first launch without legal barriers.”
Which country should you check for the Aubagio date you need?
If you tell me the country (for example, U.S. or EU/UK), I can narrow down what “loss of exclusivity” should mean in that market and what date sources typically list for Aubagio there. The answer will change based on whether you’re looking for:
- Patent expiry date(s) tied to Aubagio’s original and secondary patents
- The earliest date generics could legally launch after exclusivity/Patent barriers end
If you’re researching generic entry, what else should you verify besides the headline date?
Even after an exclusivity or patent expiration date is reached, market entry can still be delayed by:
- Patent litigation (automatic stays or other outcomes)
- Additional “late” patents in the same family
- Regulatory review timelines for generic applications
For these reasons, many market research workflows look at both the “loss of exclusivity” date and the latest relevant patent/suit information from trackers like DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/